THANK YOU FOR SUBSCRIBING
Aivita Biomedical, an Irvine, Calif.- based global biotech specialized applications, raises $15m in a Series B financing.
Financing was provided by SFC Co. Ltd., a South Korean financial specialist that is recorded on the KOSDAQ Stock Exchange.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The organization will utilize the assets to propel its clinical-stage programs, expand its consumer product contributions and acquire extra staff.
Aivita Biomedical is working along with the progression of commercial and clinical-based programs using curative and regenerative pharmaceuticals. Led by Dr. Hans Keirstead, CEO, The organization uses its expertise in stem cell growth and development and coordinated high-purity separation to empower manufacturing frameworks which bolster its business line of healthy skin products and therapeutic pipeline.
Aivita has both clinical and business programs. Its lead remedial applicant is a novel patient-particular immunotherapy for the treatment of advanced tumors, at present being utilized to treat ovarian cancer. The organization has likewise propelled a consumer skincare line, ROOT OF SKIN™, which emulates the environment of developing skin. Its proprietory actives complex, SourceCode Technology™, is only made in its clinical-grade research facilities and accessible just in ROOT OF SKIN™ items.
Check Out : TOP BIOTECH STARTUPS IN EUROPE
Check Out Review Of CIOReview : Crunchbase, Glassdoor
Check This Out : CIOReview Overview, Muckrack
More in News